FDA Approves Dupixent to Treat Eczema

Share this content:
FDA Approves Dupixent to Treat Eczema
FDA Approves Dupixent to Treat Eczema

WEDNESDAY, March 29, 2017 (HealthDay News) -- Dupixent (dupilumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe eczema that isn't well controlled by topical medication.

The active ingredient in Dupixent is an antibody (dupilumab) that binds to a protein (interleukin-4 receptor alpha subunit) that causes inflammation, and is administered subcutaneously. Its effectiveness was evaluated in clinical studies involving 2,119 patients for whom topical medication hadn't worked. Overall, participants who received Dupixent achieved clear or almost clear skin and a reduction in itch after 16 weeks of treatment.

The most common side effects included injection-site reactions, cold sores, and eye inflammation. More serious adverse effects included severe allergic reactions, conjunctivitis, and keratitis.

"FDA's approval of Dupixent demonstrates our commitment to approving new and innovative therapies for patients with skin disease," Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in a statement. "Eczema can cause significant skin irritation and discomfort for patients, so it is important to have a variety of treatment options available to patients, including those patients whose disease is not controlled by topical therapies."

The FDA granted approval of Dupixent to Regeneron Pharmaceuticals.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Warns Against Children Taking Codeine, Tramadol

FDA Warns Against Children Taking Codeine, Tramadol

Agency strengthens warning labels on these medications to address dangers

Trump Administration Offers Grants to Fight Opioid Crisis

Trump Administration Offers Grants to Fight Opioid Crisis

Money to be used to train health professionals, foster prescription drug monitoring programs

NYC to Raise Cigarette Prices to Highest in the United States

NYC to Raise Cigarette Prices to Highest in ...

Price of pack to jump from $10.50 to $13.00

is free, fast, and customized just for you!

Already a member?

Sign In Now »